Hybrid PRRT Shows Stronger Liver Tumor Radiation Dose
A pilot study of 10 patients found intraarterial delivery of 177Lu-DOTATATE delivered over three times more radiation to liver metastases than the intravenous route.
Updated on Nov. 13, 2026 in Cancer

Researchers at Memorial Sloan Kettering Cancer Center tested a hybrid intraarterial-intravenous peptide receptor radionuclide therapy in 10 patients with progressive, liver-dominant metastatic gastroenteropancreatic neuroendocrine tumors. The study was published online in The Journal of Nuclear Medicine.
Why it matters
Standard intravenous PRRT may not deliver enough radiation to liver lesions, which limits tumor control in this patient group. The hybrid approach could support a more effective, individualized treatment option if the findings hold in larger studies.
The study reports a greater than three-fold higher radiation dose to liver metastases versus intravenous delivery, with 100 percent feasibility of the intraarterial procedure across 10 patients. Survival benefit and durability beyond six months remain unresolved in this small pilot.
The players
Memorial Sloan Kettering Cancer Center
A New York-based cancer research and treatment institution widely known for oncology research and clinical trials.
Weill Cornell Medical College
A New York medical school affiliated with the lead researchers and a major academic center for clinical medicine.
The details
Patients received four cycles of 177Lu-DOTATATE every two months, with the first two cycles delivered intraarterially and the last two intravenously. Radiation exposure to staff and patients stayed within regulatory limits, with no contamination events recorded.
Timeline
Every two months during the four-cycle treatment course
Three months after treatment completion: first follow-up, 67 percent partial response
Six months after treatment completion: second follow-up, 87 percent partial response
Research announced November 12, 2026, from Reston, VA
Treatment Landscape
Current liver-directed therapies for liver-dominant metastatic gastroenteropancreatic neuroendocrine tumors reach a median progression-free survival of about 1.5 years. The hybrid intraarterial-intravenous PRRT approach is being evaluated as a possible way to improve tumor control beyond that benchmark.
For patients with liver-dominant neuroendocrine tumors, the hybrid approach may offer a different delivery route that could affect treatment planning. The study remains early-stage, so current treatment decisions depend on established options and discussions with oncology teams.
The takeaway
Delivery route can change how much radiation reaches liver tumors, which matters for individualized treatment planning. Patients considering neuroendocrine tumor therapy should ask their oncology team how localized and systemic options compare for their disease.
Further reading
For more on the disease at the center of this research, see the Cancer section.



